Gene expression profiling in myelodysplastic syndromes

ABSTRACT: Myelodysplastic syndromes (MDS) are a heterogenous group of hematopoietic stem cell disorders characterized by dysplastic blood cell formation and peripheral blood cytopenias. Up to 30% of patients with MDS will progress to a highly chemotherapy-resistant secondary acute myeloid leukemia (sAML). We identified mutations in U2AF1 in MDS patients and patients with U2AF1 mutations are at an increased risk of developing sAML.

ORGANISM(S): Homo sapiens

PROVIDER: GSE30195 | GEO | 2011/11/23

SECONDARY ACCESSION(S): PRJNA143949

REPOSITORIES: GEO